<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385162</url>
  </required_header>
  <id_info>
    <org_study_id>BGL 06-2018</org_study_id>
    <nct_id>NCT02385162</nct_id>
  </id_info>
  <brief_title>Biomarker for Glycogen Storage Diseases (BioGlycogen)</brief_title>
  <acronym>BioGlycogen</acronym>
  <official_title>Biomarker for Glycogen Storage Diseases - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CENTOGENE GmbH Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CENTOGENE GmbH Rostock</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development of a new MS-based biomarker for the early and sensitive diagnosis of Glycogen&#xD;
      Storage Diseases from plasma. Testing for clinical robustness, specificity and long-term&#xD;
      stability of the biomarker.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glycogen storage diseases (GSDs) are a group of inherited genetic disorders that cause&#xD;
      glycogen to be improperly stored in the body. People with glycogen storage diseases have a&#xD;
      buildup of abnormal amounts or types of glycogen in their tissues.&#xD;
&#xD;
      The main types of glycogen storage diseases are categorized by number and name. They include:&#xD;
&#xD;
      People with GSD I may have episodes of low blood sugar (hypoglycemia), usually during periods&#xD;
      of fasting, due to the ability to store glycogen but inability to properly release it. People&#xD;
      with GSD I typically develop an enlarged liver (hepatomegaly) from the storage of glycogen.&#xD;
      Elevations in liver function enzymes, blood fat and cholesterol levels, lactic acid, and uric&#xD;
      acid also occur. Additional features of GSD I can include decreased bone density, poor&#xD;
      growth, kidney disease, liver adenomas, and delayed puberty. Treatment primarily consists of&#xD;
      dietary management to maintain normal blood glucose levels and prevent hypoglycemia. GSD I is&#xD;
      further divided into subtypes. GSD Type Ia is caused by a deficiency of glucose-6-phosphatase&#xD;
      (G6Pase) primarily in the liver, and GSD Type Ib is caused by a deficiency of&#xD;
      glucose-6-phosphate translocase. Many of the symptoms are similar, especially early in life.&#xD;
      However, some people with Type Ib are more prone to infections given a weaker immune system.&#xD;
      GSD I is caused by a non-working change in either the G6PC gene or the SLC37A4 gene, causing&#xD;
      the deficiency of the particular enzyme. GSD I follows autosomal recessive inheritance.&#xD;
&#xD;
      Glycogen Storage Disease Type II [also known as Pompe disease, Acid Maltase Deficiency,&#xD;
      Glycogenosis Type II, Acid alpha-Glucosidase Deficiency, Lysosomal alpha-Glucosidase&#xD;
      Deficiency] Pompe disease is an inherited and often fatal disorder caused by the deficiency&#xD;
      of acid alpha-glucosidase (GAA), an enzyme needed to breakdown glycogen (sugar that is stored&#xD;
      for energy) in specialized structures in the body, called lysosomes. Patients with Pompe&#xD;
      disease have little or no GAA enzyme activity and cannot breakdown glycogen. The excess&#xD;
      glycogen accumulates and is stored in the heart, skeletal muscle and other tissues, causing&#xD;
      the progressive symptoms of Pompe disease.Glycogen Storage Disease Type III [also known as&#xD;
      Cori disease, Forbes disease, Debrancher enzyme deficiency, Limit Dextrinosis]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of a new MS-based biomarker for the early and sensitive diagnosis of Glycogen storage disease using the technique of Mass-spectometry 7,5 ml EDTA blood, saliva tube and a dry blood spot filter card</measure>
    <time_frame>24 months</time_frame>
    <description>New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testing for clinical robustness, specificity and long-term stability of the biomarker</measure>
    <time_frame>36 months</time_frame>
    <description>the goal of the study to identify and validate a new biochemical marker from the blood of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Fructose Metabolism, Inborn Errors</condition>
  <condition>Glycogen Storage Disease</condition>
  <condition>Glycogen Storage Disease Type I</condition>
  <condition>Glycogen Storage Disease Type II</condition>
  <condition>Glycogen Storage Disease Type III</condition>
  <condition>Glycogen Storage Disease Type IV</condition>
  <condition>Glycogen Storage Disease Type V</condition>
  <condition>Glycogen Storage Disease Type VI</condition>
  <condition>Glycogen Storage Disease Type VII</condition>
  <condition>Glycogen Storage Disease Type VIII</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Patients with a diagnosis of Glycogen storage diseases based upon biochemical and/or genetic criteria or profound suspicion for Glycogen storage disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Für die Entwicklung neuer Biomarker mittels Massenspektrometrie werden 10ml EDTA-Blut und&#xD;
      eine Filterkarte mit Trockenblutspots benötigt. Um die korrekte Diagnose für Glykogenosen bei&#xD;
      den Patienten zu beweisen, bei denen bis zum Studieneinschluss noch keine genetische&#xD;
      Diagnostik vorlag, werden die entsprechenden Sequenzierungen für den Nachweis der&#xD;
      Glykogenosen erfolgen. Die Analysen werden von dem Labor Centogene AG pseudonymisiert&#xD;
      durchgeführt.&#xD;
&#xD;
      CENTOGENE AG Am Strande 7 18055 Rostock Germany&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of glycogen storage disease or profound suspicion for glycogen&#xD;
        storage disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent will be obtained from the parents before any study related&#xD;
             procedures.&#xD;
&#xD;
          -  Patients of both genders older than 2 month&#xD;
&#xD;
          -  The patient has a diagnosis of glycogen storage disease or a high-grade suspicion for&#xD;
             glycogen storage disease&#xD;
&#xD;
        High-grade suspicion present, if one or more inclusion criteria are valid:&#xD;
&#xD;
          -  Positive family anamnesis for glycogen storage disease&#xD;
&#xD;
          -  Hypoglycemia&#xD;
&#xD;
          -  Growth retardation: short stature, skeletal myopathy&#xD;
&#xD;
          -  Hepatomegaly, Splenomegaly&#xD;
&#xD;
          -  Myopathy with muscle weakness&#xD;
&#xD;
          -  cardiomyopathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No Informed consent from the parents before any study related procedures&#xD;
&#xD;
          -  Patients of both genders younger than 2 month&#xD;
&#xD;
          -  No diagnosis of glycogen storage disease or no valid criteria for high-grade suspicion&#xD;
             of glycogen storage disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bauer, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Centogene GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centogene AG</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences &amp; Research Centre</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)</name>
      <address>
        <city>Mumbai</city>
        <zip>400705</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Ridgeway Hospital for Children</name>
      <address>
        <city>Colombo 8</city>
        <zip>00800c</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>India</country>
    <country>Sri Lanka</country>
  </location_countries>
  <removed_countries>
    <country>Pakistan</country>
  </removed_countries>
  <link>
    <url>http://centogene.com</url>
    <description>Centogene is one of the leading laboratories focusing on genetic testing for rare hereditary disorders. We now offer more than 2200 routine genetic and biochemical tests.</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucolipidoses</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Lysosomal Storage Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type VII</mesh_term>
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Glycogen Storage Disease</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Glycogen Storage Disease Type V</mesh_term>
    <mesh_term>Glycogen Storage Disease Type III</mesh_term>
    <mesh_term>Glycogen Storage Disease Type I</mesh_term>
    <mesh_term>Glycogen Storage Disease Type IV</mesh_term>
    <mesh_term>Fructose Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Glycogen Storage Disease Type VI</mesh_term>
    <mesh_term>Glycogen Storage Disease Type VIII</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

